Cervarix “An Innovative Vaccine to Prevent Cervical Cancer” Eduardo Ortega Eduardo Ortega- Barria Barria MD MD Vice President & Head Vice President & Head Clinical R&D and Medical Affairs Clinical R&D and Medical Affairs Latin America & the Caribbean Latin America & the Caribbean GlaxoSmithKline Biologicals GlaxoSmithKline Biologicals ® Towards Comprehensive Cervical Cancer Prevention and Control Region of the Americas Mexico City, 12-14 May 2008
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Cervarix“An Innovative Vaccine
to Prevent Cervical Cancer”
Eduardo OrtegaEduardo Ortega--BarriaBarria MDMDVice President & Head Vice President & Head Clinical R&D and Medical AffairsClinical R&D and Medical AffairsLatin America & the CaribbeanLatin America & the CaribbeanGlaxoSmithKline BiologicalsGlaxoSmithKline Biologicals
®
Towards Comprehensive Cervical Cancer Prevention and ControlRegion of the Americas
Mexico City, 12-14 May 2008
Provide best possible Provide best possible primary prevention against primary prevention against cervical cancercervical cancer
•• Broad coverage against HPV Broad coverage against HPV oncogeniconcogenic types:types:
Complete protection against HPVComplete protection against HPV--16/18 persistent 16/18 persistent infections and CIN outcomes infections and CIN outcomes up to 6.4 yearsup to 6.4 years
*Combined analysis initial efficacy study and extended follow-upATP analysis for virologic endpoints; ITT analysis for CIN endpoints
Presentation Harper D, SGO 39th Annual Meeting on Women’s Cancer, Tampa, Florida, March 9-12, 2008; Gynecol Oncol 2008; 109(1):158
n = number of subjects reporting at least one event in each groupPersistence: Cervarix® N=401; Control N=372; CIN: Cervarix® N=481; Control N=470;
100% protection against HPV 16/18 CIN2+ 100% protection against HPV 16/18 CIN2+ sustained sustained up to 6.4 yearsup to 6.4 years
1.Harper et al. Lancet. 2004; 364: 1757–652.Harper et al. Lancet 2006; 367: 1247-553.Presentation Gall S, AACR, Los Angeles, April 14-18, 2007, abstract 49004.Presentation Harper D, SGO, Tampa, Florida, March 9-12, 2008; Gynecol Oncol 2008; 109(1):158
Combined analysisCombined analysisinitial efficacy initial efficacy study and study and extended followextended follow--upup
n = number of subjects reporting at least one event in each groupITT analysis
Trials in a broad population Trials in a broad population including Latin Americaincluding Latin America
18,644 women vaccinated / 14 countries
16 %
35 %34 %
15 %
- current or prior oncogenic HPV 16/18 infection - abnormal cytology (9% low grade)- anti-HPV 16/18 serum antibodies
0
10
20
30
40
50
60
70
80
90
100
6.4 years follow-up Broad population
% E
ffica
cy C
IN2+
HPV
-16/
18
Presentation Harper D, SGO, Tampa, Florida, March 9-12, 2008; Gynecol Oncol 2008; 109(1):158; Paavonen J et al. Lancet 2007;369:2161–70
95% CI: 51.3 – 100 97.9% CI: 53.4 – 99.3
97.9% CI: 74.2 – 100
Pre-specified analysis
Causality assessment analysis*
*Based on causality assessment case assignment. The pre-specified analysis included 3 CIN2+ cases which were not considered to be causally associated with HPV-16 or HPV-18 infections acquired during the trial. Based on this analysis vaccine efficacy was 90.4% (CI 53.4–99.3)
Confirmed 100% efficacy against CIN2+Confirmed 100% efficacy against CIN2+caused by HPVcaused by HPV--16 and 1816 and 18
Protection against cytological abnormalities & CIN Protection against cytological abnormalities & CIN for any HPV types sustained for any HPV types sustained up to 6.4 Years up to 6.4 Years
Combined analysis initial efficacy study and extended followCombined analysis initial efficacy study and extended follow--upup
1 Clifford et al. Cancer Epi Biom Prev 2005;14(5); 2. Muñoz et al. N Engl J Med 2003Presentation Harper D, SGO, Tampa, Florida, March 9-12, 2008;Gynecol Oncol 2008; 109(1):158
Independent of HPV DNA statusCervical samples only; Descriptive, Conditional Exact method; ITT analysis
25–30%1
50%2
25–30%1
20–30%1
Estimated prevalence HPV 16/18
N = number of subjects included in each group; n = number of subjects reporting at least one event in each group
Cross protection against HPV 45 & 31 Cross protection against HPV 45 & 31 incident infection sustained incident infection sustained up to 6.4 years
SeropositivitySeropositivity ≥≥98%98% at all time points at all time points up to 6.4 yearsup to 6.4 years
Presentation Harper D, SGO 39th Annual Meeting on Women’s Cancer, Tampa, Florida, March 9-12, 2008
Robust typeRobust type--specific cross reactivity against specific cross reactivity against HPVHPV--45 and 3145 and 31
HPVHPV--4545Related to HPVRelated to HPV--1818
Data on File. GSKBio-WWMA_DoF001_2007 Cut-off level for seropositivity for both HPV-45 and 31: ≥59 EU/ml*up to 4.5 yrs
1,000
100
10
1
10,000
Months70 12 25–32 33–38 39–44 45–50 51–56
8.8%
100%
100% 91.7% 85.7% 90.0% 83.7% 92.3%
GM
T (E
U/m
l)
Important cause of adenocarcinoma
HPVHPV--3131Related to HPVRelated to HPV--1616
1,000
100
10
1
10,000
Months
5.9%
100%
94.1%83.3% 80.0% 87.5% 88.4% 69.2%
70 12 25–32 33–38 39–44 45–50 51–56
GM
T (E
U/m
l)
ImmunobridgeSafety / reactogenicity
Women15–25 yrs
Women15–25 yrs
Girls10–14 yrs
Women26–55 yrs
Efficacy & Immuno Findings up to 5.5 yrs
ImmunobridgeSafety / reactogenicity
Principle of Principle of ImmunobridgingImmunobridging
Month 7 Immunogenicity: GMT and Seroconversion Rate
Seropositivity definedas titer ≥8 EU/ml HPV-16
Adapted from Pedersen C et al. J Adolesc Health 2007;40:564–71
Immune response twice as high in 10Immune response twice as high in 10––14 yr olds14 yr oldsfor HPVfor HPV--16 and 1816 and 18
Seropositivity definedas titer ≥7 EU/ml HPV-18
GM
T (E
U/m
l)
17,2727,439
1
10
100
1,000
10,000
100,000
10–14 y 15–25 y1
10
100
1,000
10,000
100,000
10–14 y 15–25 y
6,864
3,070
GM
T (E
U/m
l)
100%100% 100%
100%
Efficacy study in women 15Efficacy study in women 15––25 yrs of age shows25 yrs of age showshigh and sustained antibody levelshigh and sustained antibody levels
Immunobridging to girls 10Immunobridging to girls 10––14 yrs14 yrsshows even stronger immune responseshows even stronger immune response
Harper D et al. Lancet 2006;367:1247–1255; Presentation Gall S, AACR, Los Angeles, April 14–18, 2007; Rombo L, ESPID, Porto, Portugal, May 2-4,2007
AntiAnti--HPVHPV--16 IgG16 IgG
1,000
100
10
1
10,000
Total follow-up time (months)70 12 18 25–32 33–38 39–44 45–50 51–56 57–62 63–64
AntiAnti--HPVHPV--18 IgG18 IgG
1,000
100
10
1
10,000
Total follow-up time (months)70 12 18 25–32 33–38 39–44 45–50 51–56 57–62 63–64
10–14 Year old girls
≥11-fold higher than
natural infection
≥11-fold higher than
natural infection G
MT
(EU
/ml)
GM
T (E
U/m
l)
Keam SJ & Harper DM. Drugs. 2008;68 (3):359-72;
1
10
100
1,000
10,000
100% 100%100%100%100% 100% 100%100%
ATP cohort, Seronegative at entry, month 7 results
GM
T (E
U/m
l)
HPV-16 HPV-18
15–25 years
26–35 years
36–45 years
46–55 years
Schwarz TF. J Clin Oncol 2006;24(18S):1008
Consistently high immune response Consistently high immune response across all agesacross all ages
Natural Infection
Seroconversion Seroconversion
N=437
High and sustained antibody levels in a broad High and sustained antibody levels in a broad age group over timeage group over time
Assay cut-off: 8 EU/mlATP analysisSeronegative prior to vaccination
Months
NaturalInfection
1
10
100
1,000
10,000
0 7 12 18 24 39–44 51–56 63–64
15–25 years (Efficacy study)
15–25 years26–35 years36–45 yearsAt least
8-fold higher than
natural infection
46–55 years
Keam SJ & Harper DM. Drugs. 2008;68 (3):359-72; Presentation Gall S. AACR 2007; Presentation Schwarz TF Eurogin, 2007
10,000At least 8-fold higher than
natural infection
1
10
100
1,000
0 7 12 18 24 39–44 51–56 63–64
GM
T (E
U/m
l)
HPV-16 HPV-18
0
0.5
1
1.5
2
2.5
3
0 0.5 1 1.5 2 2.5 3
R = 0.9031 R = 0.7280 R = 0.8753
-1
-0.5
0
0.5
1
1.5
2
2.5
-0.5 0 0.5 1 1.5 2 2.5
15-25 years 26-45 years 46-55 years
Strong correlation between serum and Strong correlation between serum and cervical mucosa antibody levelscervical mucosa antibody levels
Log
ratio
(ant
i-HPV
-16/
tota
l IgG
) in
CVS
Log
ratio
(ant
i-HPV
-18/
tota
l IgG
) in
CVS
- Log ratio (anti-HPV-16/total IgG) in serum - Log ratio (anti-HPV-18/total IgG) in serum
Month 24
Schwarz T. EuroGIN 2007 presentation; Stanley M, et al. Vaccine 2006;24(Suppl 3):S106–13; Giannini SL, et al. Vaccine 2006;24:5937–49
AntiAnti--HPVHPV--1616 AntiAnti--HPVHPV--1818
Higher serum Ab levels à Higher Ab levels at the mucosa -where they are most needed
15–25 years R=0.903126–45 years R=0.728046–55 years R=0.8753
15–25 years R=0.911426–45 years R=0.823546–55 years R=0.9328
Provide best possible Provide best possible primary prevention against cervical cancerprimary prevention against cervical cancer
•• Broad coverage against HPV Broad coverage against HPV oncogeniconcogenic types:types: